---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-015497"
form_type: "8-K"
ticker: "SNGX"
cik: "0000812796"
company_name: "SOLIGENIX, INC."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-23T00:33:33.522276+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Soligenix invited by BARDA to submit $25M contract proposal for Ebola/Marburg vaccines

## Summary
- BARDA invites Soligenix to submit full contract proposal for SuVax and MarVax vaccines.
- Program valued up to $25M over 5 years for SuVax Phase 1 studies, with options for MarVax.
- SuVax demonstrated 100% protection in non-human primate model with 3-dose series.
- No protective vaccines currently available for Sudan ebolavirus or Marburg marburgvirus.
- Contract award not guaranteed; requires favorable technical review and negotiation.

## SEC filing metadata
- accession: 0001558370-22-015497
- form_type: 8-K
- ticker: SNGX
- cik: 0000812796
- company_name: SOLIGENIX, INC.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/812796/000155837022015497/0001558370-22-015497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/812796/000155837022015497/tmb-20221027x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-015497
- JSON: https://secwatch.observer/filing/0001558370-22-015497.json
- Plain text: https://secwatch.observer/filing/0001558370-22-015497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.